Compassionate Use of Sodium Stibogluconate (Pentostam) for Cutaneous and Mucocutaneous New World Leishmaniasis
1 other identifier
expanded_access
N/A
1 country
1
Brief Summary
Patients with biopsy proven new world cutaneous or mucocutaneous leishmaniasis will be treated with sodium stibogluconate (Pentostam).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
July 27, 2007
CompletedFirst Posted
Study publicly available on registry
July 30, 2007
CompletedDecember 27, 2023
May 1, 2023
July 27, 2007
December 19, 2023
Conditions
Keywords
Interventions
20 mg/kg IV every day for 20 or 28 days
Eligibility Criteria
You may qualify if:
- Biopsy proven new world cutaneous or mucocutaneous leishmania
You may not qualify if:
- Prolonged QT
- Liver disease
- Pancreatitis
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
University of CA at San Francisco Hospitals and Clinics
San Francisco, California, 94143, United States
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Brian Schwartz, MD
University of CA at San Francisco
- PRINCIPAL INVESTIGATOR
Kanade Shinkai, MD
University of CA at San Francisco
Study Design
- Study Type
- expanded access
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
July 27, 2007
First Posted
July 30, 2007
Last Updated
December 27, 2023
Record last verified: 2023-05